S&P 500   4,583.34 (+1.12%)
DOW   35,386.80 (+1.02%)
QQQ   371.54 (+1.38%)
AAPL   168.36 (+1.28%)
MSFT   310.17 (+2.25%)
FB   326.16 (+2.06%)
GOOGL   2,736.46 (+1.26%)
AMZN   3,154.74 (+0.92%)
TSLA   1,024.59 (+2.91%)
NVDA   253.21 (+1.01%)
BABA   133.29 (+4.34%)
NIO   29.87 (+4.33%)
AMD   125.78 (-1.94%)
CGC   7.91 (+3.53%)
MU   87.52 (-2.76%)
GE   100.39 (-0.23%)
T   27.03 (-0.92%)
F   22.29 (-0.71%)
DIS   151.55 (+0.96%)
AMC   18.64 (+1.75%)
PFE   53.44 (-0.19%)
ACB   4.93 (+1.44%)
BA   217.31 (+0.11%)
S&P 500   4,583.34 (+1.12%)
DOW   35,386.80 (+1.02%)
QQQ   371.54 (+1.38%)
AAPL   168.36 (+1.28%)
MSFT   310.17 (+2.25%)
FB   326.16 (+2.06%)
GOOGL   2,736.46 (+1.26%)
AMZN   3,154.74 (+0.92%)
TSLA   1,024.59 (+2.91%)
NVDA   253.21 (+1.01%)
BABA   133.29 (+4.34%)
NIO   29.87 (+4.33%)
AMD   125.78 (-1.94%)
CGC   7.91 (+3.53%)
MU   87.52 (-2.76%)
GE   100.39 (-0.23%)
T   27.03 (-0.92%)
F   22.29 (-0.71%)
DIS   151.55 (+0.96%)
AMC   18.64 (+1.75%)
PFE   53.44 (-0.19%)
ACB   4.93 (+1.44%)
BA   217.31 (+0.11%)
S&P 500   4,583.34 (+1.12%)
DOW   35,386.80 (+1.02%)
QQQ   371.54 (+1.38%)
AAPL   168.36 (+1.28%)
MSFT   310.17 (+2.25%)
FB   326.16 (+2.06%)
GOOGL   2,736.46 (+1.26%)
AMZN   3,154.74 (+0.92%)
TSLA   1,024.59 (+2.91%)
NVDA   253.21 (+1.01%)
BABA   133.29 (+4.34%)
NIO   29.87 (+4.33%)
AMD   125.78 (-1.94%)
CGC   7.91 (+3.53%)
MU   87.52 (-2.76%)
GE   100.39 (-0.23%)
T   27.03 (-0.92%)
F   22.29 (-0.71%)
DIS   151.55 (+0.96%)
AMC   18.64 (+1.75%)
PFE   53.44 (-0.19%)
ACB   4.93 (+1.44%)
BA   217.31 (+0.11%)
S&P 500   4,583.34 (+1.12%)
DOW   35,386.80 (+1.02%)
QQQ   371.54 (+1.38%)
AAPL   168.36 (+1.28%)
MSFT   310.17 (+2.25%)
FB   326.16 (+2.06%)
GOOGL   2,736.46 (+1.26%)
AMZN   3,154.74 (+0.92%)
TSLA   1,024.59 (+2.91%)
NVDA   253.21 (+1.01%)
BABA   133.29 (+4.34%)
NIO   29.87 (+4.33%)
AMD   125.78 (-1.94%)
CGC   7.91 (+3.53%)
MU   87.52 (-2.76%)
GE   100.39 (-0.23%)
T   27.03 (-0.92%)
F   22.29 (-0.71%)
DIS   151.55 (+0.96%)
AMC   18.64 (+1.75%)
PFE   53.44 (-0.19%)
ACB   4.93 (+1.44%)
BA   217.31 (+0.11%)
NASDAQ:MEIP

MEI Pharma News Headlines

$2.31
+0.02 (+0.87%)
(As of 01/20/2022 09:42 AM ET)
Add
Compare
Today's Range
$2.31
$2.33
50-Day Range
$2.33
$3.37
52-Week Range
$2.28
$4.57
Volume
717 shs
Average Volume
707,485 shs
Market Capitalization
$260.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.34
Get MEI Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

MEI Pharma Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MEIP
News Sentiment

0.07

0.33

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MEIP Articles
This Week

1

1

MEIP Articles
Average Week



MEI Pharma (NASDAQ:MEIP) News Headlines Today

SourceHeadline
marketbeat.com logoMEI Pharma (NASDAQ:MEIP) Upgraded at Zacks Investment Research
marketbeat.com - January 13 at 2:04 AM
finance.yahoo.com logoThose who invested in MEI Pharma (NASDAQ:MEIP) five years ago are up 62%
finance.yahoo.com - January 15 at 4:29 PM
nasdaq.com logoThose who invested in MEI Pharma (NASDAQ:MEIP) five years ago are up 74%
nasdaq.com - January 7 at 8:35 AM
finance.yahoo.com logoDo Options Traders Know Something About MEI Pharma (MEIP) Stock We Don't?
finance.yahoo.com - December 1 at 2:38 PM
finance.yahoo.com logoMEI Pharma, Inc. (NASDAQ:MEIP) Analysts Just Cut Their EPS Forecasts Substantially
finance.yahoo.com - December 1 at 2:38 PM
finance.yahoo.com logoMEI Pharma: There’s More Upside Ahead, Says Analyst Who Made a Winning Call
finance.yahoo.com - December 1 at 2:38 PM
markets.businessinsider.com logoMEI Pharma, Kyowa Kirin Reveal Data From Zandelisib Trial In Follicular Lymphoma
markets.businessinsider.com - November 30 at 2:00 PM
businesswire.com logoMEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular ...
businesswire.com - November 30 at 9:00 AM
finance.yahoo.com logoMEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma
finance.yahoo.com - November 30 at 9:00 AM
finance.yahoo.com logoMEI Pharma to Host Webcast on November 30, 2021 at 8:00 a.m. ET Reporting Data from Ongoing Global Phase 2 TIDAL Study of Zandelisib in Patients with Follicular Lymphoma
finance.yahoo.com - November 29 at 5:16 PM
nasdaq.com logoOne MEI Pharma, Inc. (NASDAQ:MEIP) insider reduced their stake by 40% in the previous year
nasdaq.com - November 24 at 8:45 AM
finance.yahoo.com logoMEI Pharma Appoints Biotechnology Executive Sujay Kango to its Board of Directors
finance.yahoo.com - November 23 at 8:51 AM
finance.yahoo.com logoMEI Pharma Reports First Quarter Fiscal Year 2022 Results and Operational Highlights
finance.yahoo.com - November 10 at 8:36 PM
finance.yahoo.com logoMEI Pharma, Inc. (MEIP) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - November 10 at 8:36 PM
finance.yahoo.com logoMEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma
finance.yahoo.com - November 10 at 10:34 AM
finance.yahoo.com logoMEI Pharma Announces Acceptance of Three Abstracts for Presentation at the 63rd Annual American Society of Hematology Annual Meeting
finance.yahoo.com - November 4 at 10:24 AM
finance.yahoo.com logoMEI Pharma, Inc. (MEIP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
finance.yahoo.com - November 2 at 6:04 PM
finance.yahoo.com logoMEI Pharma, Inc. (NASDAQ:MEIP) Is Expected To Breakeven In The Near Future
finance.yahoo.com - October 22 at 1:54 PM
finance.yahoo.com logoMEI Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
finance.yahoo.com - September 22 at 9:56 AM
finance.yahoo.com logoCompanies Like MEI Pharma (NASDAQ:MEIP) Are In A Position To Invest In Growth
finance.yahoo.com - September 7 at 5:21 PM
finance.yahoo.com logoMEI Pharma Reports Fiscal Year 2021 Results and Operational Highlights
finance.yahoo.com - September 2 at 9:01 PM
finance.yahoo.com logoMEI Pharma, Inc. (MEIP) Reports Break-Even Earnings for Q4
finance.yahoo.com - September 2 at 9:01 PM
finance.yahoo.com logoMEI Pharma to Present at Two Healthcare Conferences
finance.yahoo.com - September 2 at 9:23 AM
finance.yahoo.com logoMEI Pharma to Release 2021 Fiscal Year End Financial Results and Provide Corporate Update on September 2, 2021
finance.yahoo.com - August 26 at 9:28 AM
finance.yahoo.com logoMei (MEIP) Begins Phase III Study for B-Cell Malignancies
finance.yahoo.com - August 18 at 4:12 PM
finance.yahoo.com logoMEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma
finance.yahoo.com - August 17 at 5:47 PM
nasdaq.com logoWhat Is The Ownership Structure Like For MEI Pharma, Inc. (NASDAQ:MEIP)?
nasdaq.com - August 10 at 12:50 PM
finance.yahoo.com logoMEI Pharma Announces Planned Chief Financial Officer Transition
finance.yahoo.com - August 5 at 4:43 PM
finance.yahoo.com logoMEI Pharma Inc (MEIP): Are Hedge Funds Right About This Stock?
finance.yahoo.com - July 29 at 8:30 PM
finance.yahoo.com logoWhat You Need To Know About MEI Pharma, Inc.'s (NASDAQ:MEIP) Investor Composition
finance.yahoo.com - July 16 at 1:39 PM
nasdaq.com logoMEI Pharma, Inc. Common Stock (MEIP)
nasdaq.com - July 15 at 7:26 PM
finance.yahoo.com logoMEI Pharma Appoints Tina C. Beamon, J.D., as Chief Compliance Officer
finance.yahoo.com - July 15 at 9:24 AM
finance.yahoo.com logoMEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - July 1 at 6:01 PM
finance.yahoo.com logoMEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
finance.yahoo.com - June 17 at 7:56 AM
benzinga.com logoMEI Pharma, Kyowa Kirin Report First Patient Dosed In Phase 2 Study For Marginal Zone Lymphoma Candidate
benzinga.com - June 7 at 12:40 PM
finance.yahoo.com logoMEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib
finance.yahoo.com - June 7 at 12:40 PM
finance.yahoo.com logoMEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO Annual Meeting
finance.yahoo.com - June 4 at 9:40 AM
finance.yahoo.com logoMEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
finance.yahoo.com - May 19 at 6:48 PM
finance.yahoo.com logoMEI Pharma, Inc. (MEIP) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - May 6 at 10:43 PM
finance.yahoo.com logoMEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights
finance.yahoo.com - May 6 at 5:37 PM
finance.yahoo.com logoMEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer
finance.yahoo.com - April 30 at 10:20 AM
finance.yahoo.com logoAnalysts Estimate MEI Pharma, Inc. (MEIP) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - April 29 at 7:02 PM
finance.yahoo.com logoMEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from U.S. Food and Drug Administration (FDA)
finance.yahoo.com - April 13 at 9:20 AM
finance.yahoo.com logoMEI Pharma Presents Positive Preclinical Data For Cancer Drug Voruciclib
finance.yahoo.com - April 12 at 1:36 PM
finance.yahoo.com logoMEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers
finance.yahoo.com - April 10 at 8:43 AM
finance.yahoo.com logoMEI Pharma to present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 5 at 8:06 AM
ca.finance.yahoo.com logoMEIP Mar 2021 5.000 call
ca.finance.yahoo.com - March 17 at 3:07 PM
ca.finance.yahoo.com logoMEIP Jun 2021 7.500 call
ca.finance.yahoo.com - March 17 at 10:00 AM
finance.yahoo.com logoMEI PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of MEI Pharma, Inc. - MEIP
finance.yahoo.com - March 13 at 2:55 AM
bloomberg.com logoMEI Pharma to Present Study at the American Association for Cancer Research (AACR) Annual Meeting 2021 Demonstrating that
bloomberg.com - March 12 at 11:51 AM
finance.yahoo.com logoMEI Pharma to Present Study at the American Association for Cancer Research (AACR) Annual Meeting 2021 Demonstrating that Voruciclib Inhibits KRAS Mutant Cancers in Pre-Clinical Models
finance.yahoo.com - March 10 at 5:46 PM
Get MEI Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.